PsoMOT 2019
Watch expert videos from the Almirall-sponsored ‘Psoriasis Management of Patients Over Time’ (PsoMOT) 2019 meeting to further your knowledge on:
- Developing treatments for psoriasis using real-world evidence studies
- The role of biologic and non-biologic treatments in psoriasis management
- Classification of psoriasis and patient-specific factors
Psoriasis Management of Patients Over Time (PsoMOT) 2019
The content below, created in collaboration with expert faculty, is from the Almirall-sponsored scientific programme PsoMOT, held in Amsterdam, 16–17 November 2019. This content informs about treatments for psoriasis, including the fumaric acid esters and biologics, such as tildrakizumab. This content is intended for HCPs only.
Professor Diamant Thaçi (University of Lübeck, Germany) and Professor Matthias Augustin (University of Hamburg, Germany) introduce the scientific programme for PsoMOT 2019.
PsoMOT 2019: real-world psoriasis studies
At Psoriasis Management of Patients Over Time (PsoMOT) 2019, Professor Luigi Naldi (Azienda Ospedaliera Papa Giovanni XXIII, Italy) and Dr Esteban Daudén (Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa, Spain) discuss the role of real-world evidence in the development of treatments for psoriasis.
Real-world psoriasis studies: expectation vs. reality – Professor Luigi Naldi (Italy)
Professor Naldi explains the limitations of randomised clinical trials, and the importance of ‘real-world evidence’ to supplement clinical trial data.
Find out how ‘big data’ and machine learning could be fundamental in developing treatments for psoriasis in the future.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
PsoMOT 2019: biologics in psoriasis management
The well-documented efficacy of biologic therapies has made them an increasingly popular choice for the treatment of psoriasis since the earliest agent was approved in 2003. Since then, a range of different biologics targeting various cytokines involved in the development and maintenance of psoriasis have become available, but their introduction has brought new challenges.
In the following videos from Psoriasis Management of Patients Over Time (PsoMOT) 2019, Professor Diamant Thaçi (University of Lübeck, Germany), Professor Stefano Piaserico (University of Padova, Italy), and Professor Ulrich Mrowietz (University Medical Centre Schleswig-Holstein, Germany) reflect on what can be done to overcome these challenges, and maximise the potential of these game-changing drugs.
New insights into the pathogenesis of psoriasis – Professor Stefano Piaserico (Italy)
Professor Stefano Piaserico explains the different cytokines involved in psoriasis pathogenesis and the benefits of inhibiting upstream targets, such as IL-23 over IL-17. He describes the potential positive impact of blocking IL-23 and Th17 in conditions other than psoriasis, and the need to consider the effects when stopping treatment.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
PsoMOT 2019: non-biologic systemic therapies in psoriasis management
In the ‘age of biologics’, is there still a place for non-biologic systemic therapies for psoriasis?
At the Psoriasis Management of Patients Over Time (PsoMOT) 2019, Professor Wolf-Henning Boehncke (University of Geneva, Switzerland), and Dr Deepak Balak (University Medical Center Utrecht, the Netherlands) discuss the appropriate use of conventional treatments for patients with psoriasis, particularly those presenting with comorbidities, and provide information on long-term treatment safety and efficacy.
Managing psoriasis patients with non-biologic systemic therapies – Professor Wolf-Henning Boehncke (Switzerland)
Professor Wolf-Henning Boehncke discusses the enduring popularity of non-biologic systemic therapies for psoriasis in the ‘age of biologics’, including giving valuable insights on their use in special patient populations.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
PsoMOT 2019: classification of psoriasis
Severity definitions in psoriasis drive the clinical decision-making process, but lack consistency across the field.
Professor Peter van de Kerkhof (Radboud University, the Netherlands), Professor Ulrich Mrowietz (University Medical Centre Schleswig-Holstein, Germany), and Professor Luigi Naldi (Azienda Ospedaliera Papa Giovanni XXIII, Italy), speaking at the Psoriasis Management of Patients Over Time (PsoMOT) 2019, discuss the importance of establishing internationally agreed psoriasis severity definitions, and what is being done to ensure that this is achieved in the future.
Masterclass on the new International Psoriasis Council guidelines – Professor Peter van de Kerkhof (the Netherlands)
Major limitations associated with the currently available psoriasis severity assessment tools represent a source of frustration for dermatologists. Find out why Professor Peter van de Kerkhof is optimistic that change is on the horizon, following the publication of the Delphi consensus from the IPC in 2019.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
PsoMOT 2019: patient-specific factors
Optimisation of psoriasis treatment strategies requires consideration of patient specific factors, from co-morbidities to what really matters to the person with psoriasis.
At Psoriasis Management of Patients Over Time (PsoMOT) 2019, Dr Esteban Daudén (Hospital Universitario de La Princesa, Institu to de Investigación Sanitaria La Princesa, Spain) and Professor Matthias Augustin (University of Hamburg, Germany) delve deep into how building a comprehensive patient profile can help inform treatment decisions, and ultimately lead to improved patient outcomes.
Professor Wolf-Henning Boehncke (University of Geneva, Switzerland) conducts a workshop that puts this principle into practice.
Psoriasis – it is not just about the skin – Dr Esteban Daudén (Spain)
Professor Esteban Daudén describes common co-morbidities associated with psoriasis, and how screening for these co-morbidities is simple and necessary. He shows that early management of psoriasis and its co-morbidities can have a beneficial effect on patient outcomes.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
PsoMOT 2019: summary and Q&A discussions
In this series of Q&A discussions at the Psoriasis Management of Patients Over Time (PsoMOT) 2019, find out how expert faculty answered questions raised by their peers.
Peter van de Kerkhof (Radboud University, the Netherlands) and Professor Diamant Thaçi (University of Lübeck, Germany) round-off proceedings with a brief summary of the meeting highlights.
Conclusions and wrap-up – Professor Peter van de Kerkhof (the Netherlands) and Professor Diamant Thaçi (Germany)
Q&A Psoriasis Discussion One – Panel
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
PsoMOT 2019 speaker biographies
Chair
Diamant Thaçi
Germany
Professor Diamant Thaçi graduated in 1989 from the University of Prishtina, Kosovo with a medical degree. From 1997–2011, Professor Thaçi was Senior Consulting Specialist in Dermatology, Director of Clinical Research, and head of the photo-dermatology division. In 2011, he was appointed as Associate Professor of Dermatology, Venereology and Allergology at the Goethe University in Frankfurt, Germany.
Since 2013, he has been a Director and full university professor at the Institute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Germany. He is also Chairman of the inflammatory board at the University Hospital Schleswig-Holstein Campus in Lübeck, Germany.
Professor Thaçi’s research experience covers immunological work in basic research and stages of clinical drug development, especially in chronic inflammatory skin diseases like psoriasis, atopic dermatitis, hidradenitis suppurativa, etc.
He is also on the editorial board for several scientific journals. He is a member of a steering committee for the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), and an active member of International Psoriasis Council (IPC), International Eczema Council (IEC), and the Skin Inflammation & Psoriasis International Network (SPIN).
Chair
Matthias Augustin
Germany
Professor Matthias Augustin has been a Professor of both Health Economics and Dermatology at the University Medical Centre, Hamburg-Eppendorf, since 2004. Since 2010, he has been the founding director of the German Centre and Institute for Health Services Research in Dermatology and Nursing (IVDP), and Head of the Comprehensive Wound Centre (CWC), and the Centre for Dermatological Research (CeDeF). Professor Augustin is also a founding director of the Hamburg Institute for Health Economics (HCHE), the largest centre for this discipline in Germany.
His research focusses on health services research, health economics, and clinical research.
He has authored 27 medical books, and about 550 scientific and medical papers. He is involved in the German skin cancer assembly, and several WHO projects.
As a dermatologist and allergologist, he holds more than two decades of clinical experience and active in his own clinic. Professor Augustin is a senior consultant to the German Ministry of Health, to several statutory health insurance companies, and to a large number of companies in the health sector. He has also been a spokesperson at the German National Parliament (Bundestag), the Federal Joint Committee (GBA), and the Institute for Quality and Efficiency in Medicine (IQWiG).
Co-chair
Peter van de Kerkhof
The Netherlands
Professor Peter van de Kerkhof started his training in Dermatology, and his research on psoriasis in 1979 at the Department of Dermatology of the Radboud University Medical Centre in Nijmegen, the Netherlands. He is currently a Senior Professor at the Radboud University.
At the same department, he was Chairman of the Department of Dermatology from 1991–2018. He led a program on psoriasis and non-melanoma skin cancer with research and innovation of care.
He served as president of various international societies, including the European Society of Dermatological Research, the European Dermatology Forum, and the International Psoriasis Council. He is editor or member of the editorial board of several international journals. He has published over 800 papers in peer reviewed journals, and gives presentations abroad on invitation.
He is Chief Medical Officer of the International Psoriasis Council, and he consults for pharmaceutical companies.
Deepak Balak
The Netherlands
Dr Deepak Balak obtained his Medical Degree and a Master of Science Degree in Biomedical Sciences in 2010 at Leiden University in Leiden, the Netherlands. At Erasmus University in Rotterdam, the Netherlands, he completed his residency training in dermatology (2017), and a PhD thesis on clinical drug evaluation of systemic treatments for psoriasis (2018).
Since November 2017, Dr Balak works as a dermatologist at the Department of Dermatology and Allergology of the University Medical Centre Utrecht in Utrecht, the Netherlands, where he combines clinical and teaching responsibilities with a research line focused on chronic inflammatory skin diseases.
His clinical focus is on the impact and management of inflammatory skin diseases, and his scientific interests include translational and pharmacological research for immune-mediated inflammatory skin diseases, such as psoriasis and atopic dermatitis. In 2019, Dr Balak was selected as an international fellow of the International Psoriasis Council.
Wolf-Henning Boehncke
Switzerland
Professor Wolf-Henning Boehncke earned his MD as a fellow of the German Scholarship Foundation in Kiel and Glasgow, and received his postdoctoral training at the National Institutes of Health in Bethesda, USA. He became Full Professor and Head of the Section of Allergy/Immunology at the Department of Dermatology of the Goethe University in Frankfurt, Germany.
Since 2012, he has been Chairman of the Division of Dermatology and Venereology at the Geneva University Hospitals, and Professor at the Department of Pathology and Immunology at the Faculty of Medicine of the University of Geneva, Switzerland. His research focuses on clinical and translational projects; namely, in cutaneous inflammation; the current focus of the lab is on the biology of the Interleukin 17 cytokine family.
He has published more than 300 peer-review articles, among them landmark papers in the New England Journal of Medicine, The Lancet, Nature Medicine, and Nature.
He has been past president of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), serves as counsellor of the International Psoriasis Council (IPC), the Scientific Board of the German Psoriasis Registry (PsoBest) and the René Tourraine Foundation.
Esteban Daudén
Spain
Dr Esteban Daudén graduated in medicine at the Complutense University of Madrid, Spain. In 1993, he received his PhD.
Dr Daudén completed his residency programme in Dermatology and Venereology at the Hospital Universitario Madrid, Spain. He then transferred to the Complutense University of Madrid as an Associate Clinical Professor in Dermatology.
Dr Daudén is a Full Professor in Dermatology at the Autonomous University of Madrid, Spain, and Chief of the Department of Dermatology at the Princess Hospital, Madrid, Spain.
Dr Daudén is a founder member of the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology (AEDV). He is also a member of numerous scientific societies and working groups including AEDV, Collegio Ibero-Latino-Americano de Dermatología, European Academy of Dermatology and Venereology, GRAPPA, EDF and ESDR.
He has also received many scientific awards, published over 290 papers in national and international journals, and contributed to 48 books. He has strong research experience from research projects, investigation studies and clinical trials.
Ulrich Mrowietz
Germany
Professor Ulrich Mrowietz is Associate Professor and Head and founder of the Psoriasis Center in the Department of Dermatology of the University Medical Center Schleswig-Holstein, in Kiel, Germany. He received his MD degree in 1992.
Professor Mrowietz’ main scientific and clinical interests are psoriasis and psoriasis management.
Professor Mrowietz was Editor-in-Chief of the Archives of Dermatological Research (2004–2018) and is author of more than 315 publications cited in the Medline database, and of numerous books and textbook chapters, including chapters in Braun-Falco’s Dermatology, and Fitzpatrick’s Dermatology in General Medicine.
Among other activities, he is a councillor of the International Psoriasis Council (IPC) , a member of the Clusters of Excellence ’Inflammation at Interfaces’ and ‘Precision Health in Schleswig-Holstein’ at the University of Kiel, a former member of the Executive Board of the German Dermatological Association, and a member of the Scientific Advisory Board of the German Psoriasis Association. He is president elect of the 6th World Psoriasis & Psoriatic Arthritis Conference 2021.
Luigi Naldi
Italy
Professor of Dermatology, Department of Dermatology, Regional Hospital of Vicenza, and GISED Study Centre, Vincenza & Bergamo, Italy.
Professor Naldi took a diploma in Classical Studies and a Degree in Industrial Design at the School of Engineering and Design of Milan, before moving to Medicine. He graduated as a medical doctor at the University of Pavia in 1981, and then spent three years as an investigator at the Laboratory of Clinical Pharmacology of the Mario Negri Institute in Milan. In 1988, he entered the clinical arena at the Department of Dermatology of the University of Milan, Bergamo General Hospital. He spent two years as an invited Professor of Dermatology at the University of Geneva (2000–2002), and qualified as a full Professor of Dermatology in Italy in 2012. He is currently head of the Department of Dermatology of the Regional Hospital in Vincenza (Italy).
His research interests are general and clinical epidemiology in Dermatology, on methods to assess the safety of medical interventions, and, more recently, on telemedicine and automisation processes in Medicine. In 1986, he established the Italian Group for Epidemiologic Research in Dermatology (GISED), which is still active. Professor Naldi has published more than 360 papers in journals.
Stefano Piaserico
Italy
Professor Stefano Piaserico is an Assistant Professor at the University of Padua, Italy, and Head of the Regional Centre for Psoriasis.
He qualified in Medicine and Surgery in 1997 from the University of Padua, and was awarded a PhD in Biochemistry and Biophysics.
His research is based on dermatology and venereology, with a key focus on psoriasis, psoriatic arthritis, organ transplant recipients, photodynamic therapy, and skin cancer. He has built up a wide portfolio of more than 110 publications in several scientific journals. He is an associate of numerous professional organisations, including the Italian Society of Dermatology and the European Academy of Dermatology and Venereology (EADV).
Laura Savage
UK
Dr Laura Savage is a Consultant Dermatologist (Leeds Teaching Hospitals NHS Trust) with a special interest in Medical Dermatology and Honorary Senior Lecturer (Faculty of Medicine and Health, University of Leeds). She graduated from the University of Edinburgh Medical School in 2005, and subsequently trained in Dermatology within the Yorkshire Deanery. Her research interests cross dermatology and rheumatology.
Dr Savage is an active member of the Group for Research in Psoriasis and Psoriatic Arthritis (GRAPPA), and co-authored their published guidelines on the detection and treatment of enthesitis.
Dr Savage has a keen interest in hidradenitis suppurativa (HS), and now runs one of a limited number of tertiary HS services in the UK. Dr Savage is an elected committee member of the British Society of Medical Dermatology.
Peter Weisenseel
Germany
Peter Weisenseel is a certified Dermatologist and Allergist with over 15 years of dermatological expertise in chronic inflammatory skin diseases and clinical studies.
Since 2012, he has been Senior Doctor at the Dermatologikum Hamburg, and Head of Medical Affairs at SCIderm GmbH, Hamburg. Prior to this, he was Medical Development Manager at Janseen-Cilag GmbH.
He completed his medical studies at Ludwig Maximilians-University (Munich) and Albertus Magnus University (Cologne) with a doctoral thesis in heart transplantation.
From 2000–2009, he served as resident/Post-Resident Doctor at the Department of Dermatology and Allergy, Ludwig Maximilians-University.
Dr Weisenseel has more than 30 PubMed listed publications.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
of interest
are looking at
saved
next event
The Psoriasis Management, Psoriasis Treatment and Psoriasis Guidelines content has been developed by EPG Health for Medthority. This content has been developed independently of the sponsor Almirall S.A, who have had no editorial input into the content. EPG Health received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
The Expert Opinion and PsoMOT content has been developed by EPG Health for Medthority in collaboration with the sponsor Almirall S.A., utilising content from their Almirall funded symposium at EADV 2021 and PsoMOT meeting in November 2019.